Breyer Capital
Edit

Breyer Capital

https://breyercapital.com
Last activity: 20.08.2026
Active
Invests in categories: AIBusinessDataFinTechHealthTechITPlatformServiceSoftwareTechnology
Breyer Capital is an independent global venture capital and private equity investor. Founded by Jim Breyer in 2006, we make long-term, idea-driven investments.
Portfolio
154
Persons
2
Mentions
104
Investment Type: Venture Capital
Investment Stage: Seed; Series A; Series B; Series C; Private Equity

Portfolio 154

DateNameWebsiteTotal RaisedLocation
10.07.2026Xaira Ther...xaira.com$1BUnited Sta...
10.07.2026Open Evide...openevidence.com$535MUnited Sta...
26.05.2026Catena Lab...catenalabs.com$48MUnited Sta...
07.05.2026ParcelBioparcelbio.com$13MUnited Sta...
13.09.2025Harbor Hea...harborhealth.com$225.5MUnited Sta...
30.08.2025Hemihemi.xyz$30MUnited Sta...
13.06.2023wasoko.comwasoko.com$125MTanzania, ...
11.06.2023Arteraartera.ai$110MUnited Sta...
11.06.2023Raytheon I...raytheonintelligenceandspace.com-United Sta...
11.06.2023Flaretheflareapp.com-United Sta...
Show more

Persons 2

DateFirst NameLast NameTitleLinkedInLocation
-CatherineRoberts-linkedin.c...-
-TedBreyerPartnerlinkedin.c...-

Mentions in press and media 104

DateTitleDescription
20.08.2026Network Bio Launches with $50 Million Financing PALO ALTO, CA, Network Bio, a biotechnology company, launched with $50 million in financing. >> Click here for more funding data on Network Bio >> To export Network Bio funding data to PDF and Excel, click here Network Bio, a b...
20.08.2026Network Bio Launches With $50 Million Financing And $30+ Million AI Partnership To Build Disease-Specific ModelsNetwork Bio has launched with $50 million in financing to build disease-specific artificial intelligence models trained on large-scale human tissue, blood, molecular and clinical datasets, as the biotechnology company seeks to apply AI to d...
19.08.2026Network Bio Raises $50M in FundingNetwork Bio, a Boston, MA-based biotechnology company building disease-specific AI models from human biological data, raised $50M in financing. Backers included Section 32, Thiel Bio, Founders Fund, Breyer Capital, Blue Venture Fund, JSL He...
19.08.2026Venture Capital & Startup Funding Roundup, August 19, 2026: Andreessen Horowitz, Battery Ventures, ICONIQ, JPMorgan Chase, Prosus & MoreVenture capital’s message over the past twelve hours is unusually coherent: investors are paying up for companies that control hard-to-replicate systems, data, infrastructure, manufacturing capacity, or regulated distribution, not simply fo...
19.08.2026Network Bio Raises $50M to Expand Disease-Specific AI PlatformNetwork Bio Raises $50M for AI Research Network Bio has raised $50 million in financing to expand its biotechnology and artificial intelligence platform. The round includes Section 32, Thiel Bio, Founders Fund and Breyer Capital. Blue Ventu...
26.05.2026Catena Labs Raises $30M in Series A FundingCatena Labs, a Boston, MA-based developer of an AI-native banking and automated financial services platform, raised $30m in Series A funding. The round was led by Acrew Capital and a16z crypto, with participation from Breyer Capital, Genera...
07.05.2026ParcelBio Raises $13M in Seed FundingParcelBio, a San Francisco, CA-based biotechnology company developing a new class of potent and durable mRNA medicines, raised $13M in Seed funding. The round was led by Breyer Capital, with participation from General Catalyst, Y Combinator...
07.05.2026ParcelBio: $13 Million Seed Financing Raised To Advance Next-Generation mRNA MedicinesParcelBio launched with $13 million in seed financing led by Breyer Capital, with participation from General Catalyst, Y Combinator, Metaplanet, SurgePoint Capital, ZAKA VC, and additional investors. The company said the financing will supp...
23.01.2026OpenEvidence Secures $250M, Valuation Soars to $12 BillionOpenEvidence, an AI-powered medical platform, closed a $250 million Series D round. It now stands at a $12 billion valuation, becoming the highest-valued healthcare AI company. This funding, co-led by Thrive Capital and DST Global, propels ...
22.01.2026OpenEvidence: $250 Million Series D At $12 Billion Valuation Raised To Expand AI ‘Medical Superintelligence’ Platform for DoctorsOpenEvidence, an AI-powered medical search platform used by clinicians, said it has raised $250 million in a Series D financing that values the company at $12 billion, positioning it as the highest-valued healthcare AI company. Thrive Capit...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In